|Series A, 7/12 ||$2.5M|
Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of Developing biomarkers predict bone metastasis That to Improve the quality of life of cancer patients. The company is a spin out of the IRB Barcelona and ICREA Research Institutions and was founded by Dr. Roger Gomis.
Our Activities are focused on the development of a diagnostic assay based on a selective single gene / protein biomarker That Predicts Those patients at risk of suffering bone-specific metastases from primary tumors. The exquisite selectivity of our lead biomarker Provides the grounds for the development of companion diagnostics - Selecting That Will patients benefit from the preventive use of anti-metastatic bone drugs, and making a step forward in the clinical standard of care using personalized medicine.